LXR and FXR modulators

1. A compound according to the formula,

or a pharmaceutically acceptable salt thereof, wherein:

J 11 is —CR 200 —;

J 21 is =N—;

R 00 is G 21 ;

R 200 is G 1 ;

R 400 is Q;

Q is C 3-6 cycloalkyl, heteroaryl or heterocyclyl, each optionally substituted with 1 to 4 R Q , or

Q is —X—Y—Z; wherein

each R Q is independently aryloxy, aralkyloxy, aryloxyalkyl, arylC 0 -C 6 alkylcarboxy, C(R 110 )═C(R 110 )—COOH, oxo, ═S, —Z, —Y′—Z, or —X—Y—Z, wherein each R Q is optionally substituted with 1 to 4 R 80 ;

R 500 is R C ;

G 21 is -J 0 -K 0 , wherein

J 0 and K 0 are independently aryl or heteroaryl, each optionally substituted with one to four R K groups;

each R K is independently hydrogen, halogen, CR 110 ═CR 110 COOR 110 , nitro, —Z, —Y—Z, or —X—Y—Z;

G 1 is -L 10 —R, wherein

L 10 is a bond, L 50 , L 60 , -L 50 -L 60 -L 50 -, or -L 60 -L 50 -L 60 -, wherein

each L 50 is independently —[C(R 150 ) 2 ] m —;

each L 60 is independently —CS—, —CO—, —SO 2 —, —O—, —CON(R 110 )—, —CONR 110 N(R 110 )—, —C(═NR 110 )—, —C(═NOR 110 )—, —C(═N—N(R 110 ) 2 )—, —C 3 -C 8 cycloalkyl-, or -heterocyclyl-,

wherein the cycloalkyl or heterocyclyl is optionally substituted with one to 4 R 140 groups;

or each L 60 is independently C 2 -C 6 alidiyl,

wherein the alidiyl chain is optionally interrupted by —C(R 110 ) 2 —, —C(R 110 ) 2 C(R 110 ) 2 —, —C(R 110 )═C(R 110 )—, —C(R 110 ) 2 O—, —C(R 110 ) 2 NR 110 —, —C≡C—, —O—, —S—, —N(R 100 )CO—, —N(R 100 )CO 2 —, —CON(R 100 )—, —CO—, —CO 2 —, —OC(═O)—, —OC(═O)N(R 100 )—, —SO 2 —, —N(R 100 )SO 2 —, or —SO 2 N(R 100 );

R is aryl, heterocyclyl, heteroaryl or —(C 3 -C 6 )cycloalkyl, wherein R is optionally substituted

with 1 to 4 R A , wherein

each R A is independently halogen, nitro, heterocyclyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, (C 3 -C 8 cycloalkyl)-C 1 -C 6 alkyl-, (C 3 -C 8 cycloalkenyl)-C 1 -C 6 alkyl-, (C 3 -C 8 cycloalkyl)-C 2 -C 6 alkenyl-, arylalkyl, aryloxy, arylC 1-6 alkoxy, C 1 -C 6 haloalkyl, SO 2 R 110 , OR 110 , SR 110 , N 3 , SOR 110 , COR 110 , SO 2 N(R 110 ) 2 , SO 2 NR 110 COR 110 , C≡N, C(O)OR 110 , CON(R 110 ) 2 , CON(R 110 )OR 110 , OCON(R 110 ) 2 , NR 110 COR 110 , NR 110 CON(R 110 ) 2 , NR 110 COOR 110 , —C(═N—OH)R 110 , —C(═S)N(R 110 ) 2 , —S(═O)N(R 110 ) 2 , —S(═O)OR 110 , —N(R 110 )S(═O) 2 R 110 , —C(═O)N(R 110 )N(R 110 ) 2 , —OC(═O)—R 110 , —OC(═O)—OR 110 or N(R 110 ) 2 , wherein

each R A is optionally substituted with 1 to 4 groups which independently are -halogen, —C 1 -C 6 alkyl, aryloxy, C 0-6 alkylSO 2 R 110 , C 0-6 alkylCOOR 110 , C 1-6 alkoxyaryl, C 1 -C 6 haloalkyl, —SO 2 R 110 , —OR 110 , —SR 110 , —N 3 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —SO 2 NR 110 COR 110 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —CON(R 110 )OR 110 , —OCON(R 110 ) 2 —NR 110 COR 110 , —NR 110 CON(R 110 ) 2 —NR 110 COOR 110 , or —N(R 110 ) 2 ;

each R 80 is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkyl(OR 110 ), C 0 -C 6 alkylOR 110 , C 0 -C 6 alkylCON(R 110 ) 2 , C 0 -C 6 alkylCOR 110 , C 0 -C 6 alkylCOOR 110 , or C 0 -C 6 alkylSO 2 R 110 ;

R C is hydrogen, halogen, nitro, cyano, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;

each R 100 is independently —R 110 , —C(═O)R 110 , —CO 2 R 110 , or —SO 2 R 110 ;

each R 110 is independently -hydrogen, —C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —C 1 -C 6 haloalkyl, or —N(R 120 ) 2 ,

wherein any of R 110 is optionally substituted with 1 to 4 radicals of R 120 ;

each R 120 is independently halogen, cyano, nitro, oxo, —B(OR 130 ) 2 , C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, (C 0 -C 6 alkyl)C═O(OR 130 ), C 0 -C 6 alkylOR 130 , C 0 -C 6 alkylCOR 130 , C 0 -C 6 alkylSO 2 R 130 , C 0 -C 6 alkylCON(R 130 ) 2 , C 0 -C 6 alkylCONR 130 OR 130 , C 0 -C 6 alkylSO 2 N(R 130 ) 2 , C 0 -C 6 alkylSR 130 , C 0 -C 6 haloalkylOR 130 , C 0 -C 6 alkylCN, —C 0 -C 6 alkylN(R 130 ) 2 , —NR 130 SO 2 R 130 , or —OC 0-6 alkylCOOR 130 ;

each R 130 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

each R 140 is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 6 haloalkyl, C 0 -C 6 alkylCON(R 110 ) 2 , C 0 -C 6 alkylCONR 110 OR 110 , C 0 -C 6 alkylOR 110 , or C 0 -C 6 alkylCOOR 110 ; and

each R 150 is independently hydrogen, halogen, OR 130 , (C 1 -C 6 )alkyl, or (C 1 -C 6 )haloalkyl, wherein

each alkyl is optionally substituted with at least one group which are each independently halogen, cyano, nitro, azido, OR 130 , C(O)R 130 , C(O)OR 130 , C(O)N(R 130 ) 2 , N(R 130 ) 2 , N(R 130 )C(O)R 130 , N(R 130 )S(O) 2 R 130 , OC(O)OR 130 , OC(O)N(R 130 ) 2 , N(R 130 )C(O)OR 130 , N(R 130 )C(O)N(R 130 ), SR 130 , S(O)R 130 , S(O) 2 R 130 , or S(O) 2 N(R 130 ) 2 ;

or two R 150 (bonded to same or different atoms) can be taken together to form a C 3 -C 6 cycloalkyl;

each X is independently —O—, —S—, or —N(R 100 )—;

each Y is independently —[C(R 150 ) 2 ] p —, or —C 2 -C 6 alkenyl, wherein p is 1, 2, 3, 4, 5, or 6;

each Y′ is independently —[C(R 150 ) 2 ] p —, —C 2 -C 6 alkenyl, C 3 -C 8 cycloalkyl, or heterocyclyl, wherein the cycloalkyl or heterocyclyl is optionally substituted with 1 to 3 Z groups;

each Z is independently —H, halogen, —OR 110 , —SR 110 , —C(═O)R 110 , —C(═O)OR 110 , —C(═O)N(R 110 ) 2 , —N(R 100 ) 2 , —N 3 , —NO 2 , —C(═N—OH)R 110 , —C(═S)N(R 110 ) 2 , —CN, —S(═O)R 110 , —S(═O)N(R 110 ) 2 , —S(═O)OR 110 , —S(═O) 2 R 110 , S(═O) 2 N(R 110 ) 2 , —NR 110 COR 110 , —N(R 110 )C(═O)N(R 110 ) 2 , —N(R 110 )COOR 110 , —N(R 110 )S(═O) 2 R 110 , —C(═O)N(R 110 )N(R 110 ) 2 , —C(═O)N(R 110 )(OR 110 ), —OC(═O)—R 110 , —OC(═O)—OR 110 , or —OC(═O)—N(R 110 ) 2 ; and

each m is independently 0, 1, 2, 3, 4, 5, or 6.

2. The compound of claim 1 wherein Q is heteroaryl or heterocyclyl, each optionally substituted with 1 to 4 R Q .

3. The compound according to claim 2 , of one of the formulae:

wherein

x and z are independently 0, 1, 2, 3, or 4; y is 0, 1, 2, or 3; and

each R J is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 110 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —NR 110 COR 110 , or —N(R 110 ) 2 .

4. A compound according to the formula,

or a pharmaceutically acceptable salt thereof, wherein:

J 11 is —CR 200 —;

J 21 is N;

R 00 is G 21 ;

R 200 is G 1 ;

R 400 is Q;

R 500 is R C ;

Q is C 3-6 cycloalkyl, heteroaryl or heterocyclyl, each optionally substituted with 1 to 4 R Q ;

R Q is independently))C(R 110 )═C(R 110 —COOH, oxo, ═S, —Z, —Y—Z, or —X—Y—Z;

G 21 is -J 0 -K 0 , wherein

J 0 and K 0 are independently aryl or heteroaryl, each optionally substituted with one to four R K groups;

each R K is independently hydrogen, halogen, nitro, —Z, —Y—Z, or —X—Y—Z;

G 1 is -L 10 -R, wherein

L 10 is a bond or —[C(R 150 ) 2 ] m —;

R is aryl or heteroaryl, wherein R is optionally substituted with 1 to 4 R A , wherein

each R A is independently halogen, nitro, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, SO 2 R 110 , OR 110 , SR 110 , SOR 110 , COR 110 , SO 2 N(R 110 ) 2 , SO 2 NR 110 COR 110 , C≡N, C(O)OR 110 , CON(R 110 ) 2 , CON(R 110 )OR 110 , OCON(R 110 ) 2 , NR 110 COR 110 , NR 110 CON(R 110 ) 2 , NR 110 COOR 110 , —C(═N—OH)R 110 , —C(═S)N(R 110 ) 2 , —S(═O)N(R 110 ) 2 , —S(═O)OR 110 , —N(R 110 ) 2 R 110 , —C(═O)N(R 110 )N(R 110 ) 2 , —OC(═O)—R 110 , —OC(═O)—OR 110 or N(R 110 ) 2 ;

R C is hydrogen, halogen, nitro, cyano, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;

each R 100 is independently —R 110 , —C(═O)R 110 , —CO 2 R 110 , or —SO 2 R 110 ;

each R 110 is independently -hydrogen, —C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —C 1 -C 6 haloalkyl, or —N(R 120 ) 2 , wherein any of R 110 is optionally substituted with 1 to 4 radicals of R 120 ;

each R 120 is independently halogen, cyano, nitro, oxo, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, (C 0 -C 6 alkyl)C=O(OR 130 ), C 0 -C 6 alkylOR 130 , C 0 -C 6 alkylCOR 130 , C 0 -C 6 alkylSO 2 R 130 , C 0 -C 6 alkylCON(R 130 ) 2 , C 0 -C 6 alkylCONR 130 OR 130 , C 0 -C 6 alkylSO 2 N(R 130 ) 2 , C 0 -C 6 alkylSR 130 , C 0 -C 6 haloalkylOR 130 , C 0 -C 6 alkylCN, —C 0 -C 6 alkylN(R 130 ) 2 , —NR or —OC 0-6 alkylCOOR 130 ;

each R 130 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

each R 150 is independently hydrogen, halogen, OR 130 , (C 1 -C 6 )alkyl, or (C 1 -C 6 )haloalkyl;

or two R 150 (bonded to the same or different atoms) taken together to form a C 3-6 cycloalkyl;

each X is independently —O—, —S—, or —N(R 100 )—;

each Y is independently —[C(R 150 ) 2 ] p —, or —C 2 -C 6 alkenyl, wherein p is 1, 2, 3, 4, 5, or 6;

each Z is independently —H, halogen, —OR 110 , —SR 110 , —C(═O)R 110 , —C(═O)OR 110 , —C(═O)N(R 110 ) 2 , —N(R 110 ) 2 , —N 3 , —NO 2 , —C(═N—OH)R 110 , —C(═S)N(R 110 ) 2 , —CN, —S(═O)R 110 , —S(═O)N(R 110 ) 2 , —S(═O)OR 110 , —S(═O) 2 R 110 , S(═O) 2 N(R 110 ) 2 , —NR 110 COR 110 , —N(R 110 )C(═O)N(R 110 ) 2 , —N(R 110 )COOR 110 , —N(R 110 )S(═O) 2 R 110 , —C(═O)N(R 110 )N(R 110 ) 2 , —C(═O)N(R 110 )(OR 110 ), —OC(═O)—R 110 , —OC(═O)—OR 110 , or —OC(═O)—N(R 110 ) 2 ; and

each m is independently 0, 1, 2, 3, 4, 5, or 6.

5. The compound according to claim 4 , wherein G21 is -J 0 -K 0 , wherein J 0 and K 0 are independently thienyl, pyrrolyl, furyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, phenyl, pyridyl, pyrazinyl, or pyrimidinyl, each optionally substituted with one to four R K groups.

6. The compound according to claim 5 , wherein J 0 is phenyl optionally substituted with one or two R K groups; and K 0 is phenyl, pyridyl, pyrazinyl, or pyrimidinyl, each optionally substituted with one to four R K groups.

7. The compound according to claim 6 , wherein K 0 is phenyl optionally substituted with 1 to 3 R K groups.

8. The compound according to claim 7 , wherein K 0 is phenyl substituted with at least one S(═O) 2 (C 1-6 alkyl) group.

9. The compound according to claim 4 , wherein G 1 is -L 10 -R, wherein L 10 is a bond; and R is phenyl optionally substituted with 1 or 2 R A .

10. The compound according to claim 9 , wherein each R A is independently fluoro, chloro, methyl, trifluoromethyl, —OR 110 , —SR 110 , —SO 2 R 110 , or —C(O)OR 110 .

11. The compound according to claim 9 , wherein R is phenyl substituted with at least one chloro group.

12. The compound according to claim 9 , wherein R is phenyl substituted with at least one trifluoromethyl group.

13. The compound according to claim 4 , wherein G 1 is -L 10 -R, wherein L 10 is —[C(R 150 ) 2 ] m —, wherein m is 1 or 2; and R is phenyl optionally substituted with 1 or 2 R A .

14. The compound according to claim 13 , wherein each R A is independently fluoro, chloro, methyl, trifluoromethyl, N(R 110 ) 2 , N(R 110 )CON(R 110 ) 2 , CON(R 110 ) 2 , SO 2 R 110 , OR 110 , SR 110 , or C(O)OR 110 .

15. The compound according to claim 13 , wherein R is phenyl substituted with at least one chloro group.

16. The compound according to claim 13 , wherein R is phenyl substituted with at least one trifluoromethyl group.

17. The compound according to claim 4 , wherein Q is a 5-membered heteroaryl optionally substituted with 1 to 4 R Q .

18. The compound according to claim 17 , wherein Q is pyrrolyl, pyrazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl, each optionally substituted with 1 to 4 R Q .

19. The compound according to claim 18 , wherein Q is 1,3-thiazolyl; 1,2,4-oxadiazolyl; 1,2,5-oxadiazolyl; 1,3,4-oxadiazolyl; 1,3,5-oxadiazolyl; pyrrolyl; thienyl; pyrazolyl; imidazolyl; furyl; isoxazolyl; or 1,3,5-thiadiazolyl, each optionally substituted with 1 or 2 R Q .

20. The compound according to claim 4 , Q is a 5-membered heterocyclyl optionally substituted with 1 to 4 R Q .

21. The compound according to claim 4 , Q is imidazolidinyl, oxazolidinyl, thiazolidinyl, pyrrolidinyl, dioxolanyl, oxathiolanyl, dithiolanyl, imidazolinyl, oxazolinyl, thiazolinyl, 1,3-dioxolyl, 1,3-oxathiolyl, or 1,3-dithiolyl, each optionally substituted with 1 to 4 R Q .

22. The compound according to claim 4 , Q is 4,5-dihydro-1,3-oxazolyl; 4,5-dihydro-1,3-thiazolyl; 4,5-dihydro-1H,1′H-2,4′-imidazolyl; pyrrolidinyl; piperidinyl; tetrahydropyranyl; 3,4-dihydro-2H-pyranyl; oxetanyl, or azetidinyl, each optionally substituted with 1 or 2 R Q .

23. The compound according to claim 4 , Q is C 3-6 cycloalkyl optionally substituted with 1 to 4 R Q .

24. The compound according to claim 23 , Q is cyclopropyl or cyclopentyl optionally substituted with 1 or 2 R Q .

25. The compound according to claim 23 , Q is cyclopropyl or cyclopentyl, substituted with CN, OH or OC 1-6 alkyl.

26. The compound according to claim 4 , of one of the formulae:

wherein

x and z are independently 0, 1, 2, 3, or 4; y is 0, 1, 2, or 3; and

each R J is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 110 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —NR 110 COR 110 , or —N(R 110 ) 2 .

27. The compound according to claim 26 , wherein Q is a 5-membered heteroaryl optionally substituted with 1 to 4 R Q .

28. The compound according to claim 26 , wherein Q is pyrrolyl, pyrazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl, each optionally substituted with 1 to 4 R Q .

29. The compound according to claim 28 , wherein Q is 1,3-thiazolyl; 1,2,4-oxadiazolyl; 1,2,5-oxadiazolyl; 1,3,4-oxadiazolyl; 1,3,5-oxadiazolyl; pyrrolyl; thienyl; pyrazolyl; imidazolyl; furyl; isoxazolyl; or 1,3,5-thiadiazolyl, each optionally substituted with 1 or 2 R Q .

30. The compound according to claim 26 , Q is a 5-membered heterocyclyl optionally substituted with 1 to 4 R Q .

31. The compound according to claim 26 , Q is imidazolidinyl, oxazolidinyl, thiazolidinyl, pyrrolidinyl, dioxolanyl, oxathiolanyl, dithiolanyl, imidazolinyl, oxazolinyl, thiazolinyl, 1,3-dioxolyl, 1,3-oxathiolyl, or 1,3-dithiolyl, each optionally substituted with 1 to 4 R Q .

32. The compound according to claim 26 , Q is 4,5-dihydro-1,3-oxazolyl; 4,5-dihydro-1,3-thiazolyl; 4,5-dihydro-1H,1′H-2,4 ′-imidazolyl; pyrrolidinyl; piperidinyl; tetrahydropyranyl; 3,4-dihydro-2H-pyranyl; or azetidinyl, each optionally substituted with 1 or 2 R Q .

33. The compound according to claim 26 , Q is C 3-6 cycloalkyl optionally substituted with 1 to 4 R Q .

34. The compound according to claim 33 , Q is cyclopentyl or cyclopropyl optionally substituted with 1 or 2 R Q .

35. The compound according to claim 33 , Q is cyclopentyl or cyclopropyl, substituted with OH or OC 1-6 alkyl.

36. The compound according to claim 26 , of one of the formulae:

wherein

x and z are independently 0, 1, 2, or 3; y is 0, 1, or 2; and

each R K and R J is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 110 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —NR 110 COR 110 or —N(R 110 ) 2 .

37. The compound according to claim 36 , of one of the formulae:

wherein

x and z are independently 0 or 1;

y is 0, 1, or 2;

each R K and R J is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 110 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —NR 110 COR 110 or —N(R 110 ) 2 .

38. The compound according to claim 37 , of one of the formulae:

wherein

x and z are independently 0 or 1;

y is 0, 1, or 2;

each R A is independently halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; and

each R K and R J is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 110 , —SO 2 R 110 , —COR 110 , —SO 2 N(R 110 ) 2 , —C≡N, —C(O)OR 110 , —CON(R 110 ) 2 , —NR 110 COR 110 or —N(R 110 ) 2 .

39. A compound according to the formula,

or a pharmaceutically acceptable salt thereof, wherein:

Q is C 3-6 cycloalkyl; 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl, each optionally substituted with one or two R Q ;

R Q is independently oxo, ═S, —Z, or —Y—Z;

G 21 is J 0 -K 0 , wherein

J 0 and K 0 are phenyl, each optionally substituted with one or two R K groups;

each R K is independently halogen, —Z, or —Y—Z;

G 1 is -L 10 -R, wherein

L 10 is a bond or —[C(R 150 ) 2 ]—;

R is phenyl, wherein R is optionally substituted with one or two R A groups, wherein

each R A is independently halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;

R C is —Z;

each R 110 is independently hydrogen or —C 1 -C 6 alkyl;

each R 110 is independently hydrogen, halogen, or (C 1 -C 6 )alkyl;

each Y is independently -[C(R 150 ) 2 ] 1 , wherein q is 1, 2, 3, 4, 5, or 6; and

each Z is independently H, halogen, cyano, —OR 110 , —C(═O)R 110 , —C(═O)OR 110 , or —S(═O) 2 R 110 .

40. The compound of claim 39 wherein:

each R Q is independently halogen, C 1-6 alkyl, CF 3 , CN, oxo, ═S, C 0-6 alkylOR 110 , —C(O)R 110 or —C(═O)OR 110 ;

each R K is independently halogen or —S(═O) 2 R 110 ;

each R A is halogen or C 1 -C 6 haloalkyl; and

R C is H.

41. The compound according to claim 1 selected from the compounds listed in Tables 16 and 20.

42. A composition comprising a compound of claim 1 , 4 , 39 , or 41 and one or more pharmaceutically acceptable carriers.

43. A method of treating or ameliorating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , 4 , 39 or 41 , wherein the disease or disorder is hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, lipodystrophy, hyperglycemia, diabetes mellitus, dyslipidemia, or diabetes.

44. A method of treating or ameliorating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , 4 , 39 or 41 , wherein the disease or disorder is atherosclerosis, gallstone disease, acne vulgaris, acneiform skin conditions, inflammation, obesity, or xanthomas.

45. A method of treating or ameliorating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , 4 , 39 or 41 , wherein the disease or disorder is multiple sclerosis.